Oppenheimer Maintains Neurocrine Biosciences (NBIX) Outperform Recommendation
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Fintel reports that on October 6, 2023, Oppenheimer maintained coverage of Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform recommendation.
